Chugai Pharmaceutical said on April 1 that it will divest its gastritis and peptic ulcer treatment Ulcerlmin (sucralfate) to Fuji Chemical Industries, with its marketing authorization transfer slated by the end of September. Originated and developed by Chugai, Ulcerlmin has…
To read the full story
Related Article
- Nichi-Iko Gets Distribution Rights to Chugai’s Ulcerlmin
July 23, 2019
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





